Head to Head Comparison: Kyverna Therapeutics (KYTX) and Its Peers

Kyverna Therapeutics (NASDAQ:KYTX) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Kyverna Therapeutics to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 15.6% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Kyverna Therapeutics has a beta of 2.57, suggesting that its stock price is 157% more volatile than the S&P 500. Comparatively, Kyverna Therapeutics’ competitors have a beta of -4.48, suggesting that their average stock price is 548% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Kyverna Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	5	1	3.00
Kyverna Therapeutics Competitors	1970	5450	14059	303	2.58

Kyverna Therapeutics presently has a consensus price target of $18.33, indicating a potential upside of 800.90%. As a group, “Biological products, except diagnostic” companies have a potential upside of 120.27%. Given Kyverna Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than its competitors.

Profitability

This table compares Kyverna Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
Kyverna Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Valuation and Earnings

This table compares Kyverna Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	-$60.37 million	-0.59
Kyverna Therapeutics Competitors	$575.17 million	-$70.96 million	-2.01

Kyverna Therapeutics’ competitors have higher revenue, but lower earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Kyverna Therapeutics beats its competitors on 10 of the 13 factors compared.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.